Therapy Areas
Novartis is uniquely diversified across therapy areas with exposure to cutting-edge technology platforms. We have arguably the richest and broadest pipeline in the industry with more than 65 New Molecular Entities in development. Please select your therapy area of interest to connect to one of our specialist, partnering professionals.
Seeking transformative immune-regulating or tolerance-inducing approaches to rebuild the immune system.
Enrico Funhoff
Contact me for partnerships before clinical PoC.
Seeking first in class and well differentiated/ best in class treatments for moderate-severe Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Vitiligo, Alopecia Areata and severe forms of Acne as well as curative treatments for rare skin diseases.
Enrico Funhoff
Contact me for partnerships before clinical PoC.
Markus Kalousek
Contact me for partnerships after clinical PoC.
Seeking transformative approaches to address genetic diseases.
Leah Bloom
Senior Vice President and Head of Novartis Gene Therapies’ External Innovation and Strategic Alliances Tea
Contact me for strategic alliances
Blake Arnold
Senior Director, Corporate Development (leads late-stage BD).
Contact me for late stage partnerships
Adam Simpson
Senior Director, Business Development (leads early-stage BD).
Contact me for late stage partnerships
Liz Hines
Senior Manager, External Innovation (supports late-stage BD and other external innovation initiatives).
Contact me for early stage partnerships
Dan Cojocaru
Secondee, Business Development (supports early-stage BD).
Interested in targets for the underlying disease pathology in neurodegenerative diseases, advanced therapeutic options in refractory psychiatric disorders and take to heart pediatric neurological and neuromuscular diseases.
ChiChi Zhu
Contact me for partnerships before clinical PoC.
Patrick Mueller
Contact me for partnerships after clinical PoC.
We develop and deliver life-changing medicines for diseases and conditions from front to back of the eye, enabled by data, transformative technologies and partnerships. Our ophthalmic products reach more than 150M people each year, from preterm infants to the elderly.
Adam Feire
Contact me for partnerships before clinical PoC.
Dimitrios Lizos
Contact me for partnerships after clinical PoC.
We are looking for partners to expand our portfolio with innovative and potentially transformative agents with a primary focus in Asthma, COPD, IPF, life threatening hospital conditions, food allergy as well as digital solutions to address unmet need in asthma and COPD.
Dominic Ehrismann
Contact me for partnerships before clinical PoC.
Ken Shaw
Contact me for partnerships after clinical PoC.
Seeking projects with First in Class or Best in Class potential for moderate-severe Rheumatoid & Psoriatic Arthritis, Ankylosing Spondylitis, primary Sjoegren and Lupus with emphasis on oral treatments at par with biologics, or biologics with clear differentiation versus standard of care.
Enrico Funhoff
Contact me for partnerships before clinical PoC.
Markus Kalousek
Contact me for partnerships after clinical PoC.
We accept that innovation happens outside of areas of interest- we are still prepared to discuss transformational areas we may have missed. We have a special team for you to talk with.
Ken Shaw
Contact me for partnerships before clinical PoC.
